Literature DB >> 32632564

Visualization of translocator protein (18 kDa) (TSPO) in the retina of diabetic retinopathy rats using fluorine-18-DPA-714.

Yujing Zhou1, Yinghui Ou1, Zizhao Ju1, Xiaoqing Zhang1, Lingling Zheng1, Jun Li1, Yu Sun1, Xingdang Liu2.   

Abstract

OBJECTIVES: To investigate the feasibility of a noninvasive method for imaging translocator protein (18 kDa) (TSPO) in the retina of diabetic retinopathy (DR) rats using fluorine-18-DPA-714 ([18F]-DPA-714) micro-positron emission tomography (PET)/X-ray computed tomography (CT).
METHODS: Sprague-Dawley (SD) rats were intraperitoneally injected with streptozocin (STZ) (65 mg kg-1, ip) to induce diabetes mellitus (DM). The TSPO in both eyes was detected by PET/CT using [18F]-DPA-714 12 weeks after the establishment of the DM model. The mean standardized uptake value (SUVmean) was analyzed. Western blot and quantitative real-time polymerase chain reaction (PCR) were performed to detect the TSPO protein and mRNA levels in the retina.
RESULTS: PET/CT results showed that the SUV of [18F]-DPA-714 was markedly reduced in the retina of DR rats compared with that of normal controls 12 weeks after diabetes induction. The SUVmean of regions of interest (ROIs) in the retinas of DR and normal control rats was 0.883 ± 0.078 and 2.525 ± 0.213 (P < 0.001), respectively. The results of PET/CT were in line with the Western blots and quantitative real-time PCR.
CONCLUSIONS: The PET results demonstrated that TSPO was decreased in the early stage of DR. [18F]-DPA-714 PET/CT appears to be a useful noninvasive imaging method for detecting TSPO in the retina. A decrease in the TSPO level in the retina may play an important role in the development of DR.

Entities:  

Keywords:  Diabetic retinopathy; Positron emission tomography; Translocator protein; [18F]-DPA-714

Mesh:

Substances:

Year:  2020        PMID: 32632564     DOI: 10.1007/s12149-020-01495-2

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  29 in total

1.  LXR and TSPO as new therapeutic targets to increase the levels of neuroactive steroids in the central nervous system of diabetic animals.

Authors:  Nico Mitro; Gaia Cermenati; Silvia Giatti; Federico Abbiati; Marzia Pesaresi; Donato Calabrese; Luis Miguel Garcia-Segura; Donatella Caruso; Roberto C Melcangi
Journal:  Neurochem Int       Date:  2012-03-03       Impact factor: 3.921

Review 2.  Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function.

Authors:  Vassilios Papadopoulos; Mario Baraldi; Tomás R Guilarte; Thomas B Knudsen; Jean-Jacques Lacapère; Peter Lindemann; Michael D Norenberg; David Nutt; Abraham Weizman; Ming-Rong Zhang; Moshe Gavish
Journal:  Trends Pharmacol Sci       Date:  2006-07-05       Impact factor: 14.819

3.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

Authors:  N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda
Journal:  Diabetes Res Clin Pract       Date:  2018-02-26       Impact factor: 5.602

4.  Efficacy of treatment after measurable diabeticlike retinopathy in galactose-fed rats.

Authors:  W G Robison; N M Laver; J L Jacot; M L Chandler; B M York; J P Glover
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-05       Impact factor: 4.799

Review 5.  The Translocator Protein 18 kDa (TSPO) and Its Role in Mitochondrial Biology and Psychiatric Disorders.

Authors:  Vladimir M Milenkovic; Rainer Rupprecht; Christian H Wetzel
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

Review 6.  Is there a mitochondrial signaling complex facilitating cholesterol import?

Authors:  Vassilios Papadopoulos; Jun Liu; Martine Culty
Journal:  Mol Cell Endocrinol       Date:  2007-02-05       Impact factor: 4.102

Review 7.  Peripheral benzodiazepine receptor (PBR) new insight in cell proliferation and cell differentiation review.

Authors:  Lorenzo Corsi; Elisa Geminiani; Mario Baraldi
Journal:  Curr Clin Pharmacol       Date:  2008-01

8.  Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy.

Authors:  Thierry Bordet; Bruno Buisson; Magali Michaud; Jean-Louis Abitbol; Fabien Marchand; John Grist; Emile Andriambeloson; Marzia Malcangio; Rebecca M Pruss
Journal:  J Pharmacol Exp Ther       Date:  2008-05-20       Impact factor: 4.030

Review 9.  Diabetic retinopathy: more than meets the eye.

Authors:  Thomas W Gardner; David A Antonetti; Alistair J Barber; Kathryn F LaNoue; Steven W Levison
Journal:  Surv Ophthalmol       Date:  2002-12       Impact factor: 6.048

Review 10.  The progress in understanding and treatment of diabetic retinopathy.

Authors:  Alan W Stitt; Timothy M Curtis; Mei Chen; Reinhold J Medina; Gareth J McKay; Alicia Jenkins; Thomas A Gardiner; Timothy J Lyons; Hans-Peter Hammes; Rafael Simó; Noemi Lois
Journal:  Prog Retin Eye Res       Date:  2015-08-18       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.